Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for freezing of gait in Parkinson's disease
NL-OMON60375Phase 3Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atomoxetine in Parkinson's disease (PD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Freezing of gait severity in dopaminergic OFF-state. Started Jan 2026; status: recruiting.
02
Drugs
atomoxetine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON60375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60375.